By Michael Gwarisa The recently introduced long-acting cabotegravir (CAB-LA) for HIV prevention has seen more users returning to get the second dose post their first jab, with data showing that the injectable drug has recorded a continuity rate over 90% since roll out in April, 2024. Currently, the Injectable PrEP is being administered in PrEP study sites in Harare, Mature and Bulawayo and is targeting mainly groups at high risk of HIV, namely Female Sex Workers (FSW), Adolescent Girls and Young Women (AGYW) and Men who have Sex with other…
Read MoreCAB-LA Enjoys High Continuity Rates Among PrEP Users In Zimbabwe
